[Pulmonary hypertension in chronic lung diseases]

Area of Science:

• Cardiology
• Pulmonology
• Respiratory Medicine

Context:

• Pulmonary hypertension (PH) frequently complicates chronic obstructive lung disease (COPD) and diffuse parenchymal lung diseases (DPLD), including idiopathic pulmonary fibrosis (IPF) and sarcoidosis.
• Patients with combined pulmonary fibrosis and emphysema (CPFE) exhibit a heightened susceptibility to developing PH.
• Accurate diagnosis and differentiation between PH groups are crucial for appropriate management, especially distinguishing Group 1 PH from Group 3 PH (lung disease-related PH).

Purpose:

• To provide clear definitions and diagnostic criteria for classifying PH in patients with COPD, IPF, and CPFE.
• To identify a distinct subgroup of patients with severe PH within chronic lung diseases who exhibit significant vascular abnormalities and poor prognosis.
• To guide research and clinical management strategies for patients with severe PH associated with chronic lung diseases.

Summary:

• The study defines criteria for PH in COPD, IPF, and CPFE, categorizing patients into those without PH, with PH, and with severe PH based on mean pulmonary artery pressure (mPAP) and cardiac index (CI).
• A 'severe PH group' is identified, characterized by vascular remodeling and exhausted circulatory reserve, presenting with disproportionate exertional dyspnea, low diffusion capacity, and rapid oxygen desaturation.
• This severe PH subgroup, representing a minority of chronic lung disease patients, requires specialized evaluation and care at expert centers.

Impact:

• Establishes standardized definitions for PH in common lung diseases, aiding clinical assessment and research.
• Highlights a clinically significant subgroup of patients with severe PH and poor prognosis, necessitating focused therapeutic strategies.
• Recommends that clinical trials for PH medications not yet approved for Group 3 PH should prioritize this severe PH population and emphasizes the need for expert center referral.